Send to

Choose Destination

See 1 citation found by title matching your search:

Br J Dermatol. 2018 Nov;179(5):1072-1080. doi: 10.1111/bjd.16705. Epub 2018 Aug 14.

Secukinumab shows high efficacy irrespective of HLA-Cw6 status in patients with moderate-to-severe plaque-type psoriasis: SUPREME study.

Author information

Dermatology Unit, Department of Biomedical Sciences, Humanitas University, Via Alessandro Manzoni 113, Rozzano-Milan, 20089, Italy.
Skin Pathology Laboratory, IRCCS Istituto Clinico Humanitas, Via Alessandro Manzoni 113, Rozzano-Milan, 20089, Italy.
Dermatology, Department of Systems Medicine, Policlinico di Tor Vergata, University of Rome Tor Vergata, Viale Oxford 81, Rome, 00133, Italy.
Dermatology Section, Department of Clinical Medicine and Immunological Science, University of Siena, Hospital S. Maria alle Scotte, viale Bracci, Siena, Italy.
Dermatology Department, Grande Ospedale Metrapolitano, Bianchi Melacrino Morelli, 89124, Reggio Calabria, Italy.
Section of Clinical, Allergological and Venereological Dermatology, Department of Medicine, University of Perugia, Piazza Menghini 1, Perugia, 06129, Italy.
Novartis Farma S.p.A., Via Saronnino, Origgio, VA, 21042, Italy.



Understanding genetic variations is important in predicting treatment response and forms the basis for identifying new pharmacogenetic and pharmacogenomic targets for psoriasis treatment. There are limited data on the efficacy of secukinumab in relation to genetic markers.


To evaluate the efficacy and safety of secukinumab 300 mg in HLA-Cw6-positive (Cw6-POS) and HLA-Cw6-negative (Cw6-NEG) patients with moderate-to-severe chronic plaque-type psoriasis.


SUPREME was a 24-week, phase IIIb study with an extension period up to 72 weeks. Primary end point was Psoriasis Area Severity Index (PASI) 90 response rate after 16 weeks.


In total, 434 patients were recruited: 185 (42·6%) were Cw6-POS and 246 (56·7%) were Cw6-NEG (three not assessed). Mean ± SD age was 45·2 ± 13·2 years (Cw6-POS 42·7 ± 13·1; Cw6-NEG 47·2 ± 12·9). The baseline PASI score was comparable between the cohorts [Cw6-POS 20·7 ± 8·99; Cw6-NEG 21·5 ± 9·99 (P = 0·777)]. At week 16, PASI 90 was achieved in 80·4% of Cw6-POS and 79·7% of Cw6-NEG patients (difference 0·76; 95% confidence interval -7·04 to 8·23). No differences in absolute PASI at week 16 (Cw6-POS 1·36 ± 3·58; Cw6-NEG 1·18 ± 2·29) were observed. The overall safety profile of secukinumab was consistent with that previously reported. No statistically significant difference was detected in the rate of treatment-emergent adverse events [Cw6-POS 42·7%; Cw6-NEG 49·6% (P = 0·295)]. A high PASI 90 response was achieved with secukinumab with a fast reduction in absolute PASI.


Determination of HLA-Cw6 status for secukinumab therapy is unnecessary, as it is highly effective regardless of HLA-Cw6 status.


Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center